<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38370097</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1937-8688</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>Suppl 2</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>The Pan African medical journal</Title><ISOAbbreviation>Pan Afr Med J</ISOAbbreviation></Journal><ArticleTitle>Innovative strategies developed to mitigate the impact of COVID-19 pandemic on polio surveillance in Nigeria, 2020.</ArticleTitle><Pagination><StartPage>10</StartPage><MedlinePgn>10</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.11604/pamj.supp.2023.45.2.38261</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">following the spread of the COVID-19 pandemic to Nigeria, the Federal Government of Nigeria restricted human and vehicular movements to curb the spread of the disease. This action had a negative impact on Acute Flaccid Paralysis (AFP) surveillance, with a resultant reduction in the number of AFP cases reported. This paper describes the impact of the COVID-19 pandemic on poliovirus surveillance in Nigeria and the proactive interventions by Nigeria´s polio program to mitigate the impact of COVID-19 on polio surveillance.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">nine innovative strategies were implemented in all 774 Local Government Areas (LGA) of the 36 states and Federal Capital Territory (FCT) of the country. These strategies were developed by the national surveillance officers and operationalized by sub-national surveillance officers with different strategies starting at different epidemiological weeks from week 14 to 23, 2020. Many of the strategy innovations were technology-based and included: the use of mobile phones to send the AFP case definition and video by WhatsApp or by SMS, the use of state-specific toll-free numbers and Mobile Telephone Network (MTN) (mobile service provider) CallerfeelTM to community informants (CI) who were the main targets of the interventions to increase case detection and reporting. Others included the use of abridged e-surveillance integrated supportive supervision (ISS) checklists, virtual monthly DSNO meetings, and batched AFP stool specimen transportation network.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">compared to the same period in 2019, the cumulative rate of AFP case detection and reporting had gradually declined from 39.1% in January to 16.7% before the commencement of the interventions in week 20, 2020. However, the detection and reporting increased by 57.% from week 20 to week 47 compared to the same period in 2019. This is because with COVID-19, hospital visitation dropped, and the sick remained in the communities, so the CI network was relied on to detect and report AFP cases. The cumulative proportion of AFP cases reported by community informants as of week 47 increased from 13% in 2018 to 21% in 2020. This indicates an increase of 38%. Thirty-five AFP cases were detected and reported using the MTN Caller Feel strategy, while 15 cases were reported through state-specific toll-free numbers.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">the implementation of the innovative strategies was able to mitigate the low AFP case detection and reporting observed at the initial stage of the COVID-19 pandemic. The use of technology facilitated reaching the CI network, which was more instrumental in detecting and reporting the cases.</AbstractText><CopyrightInformation>©Aboyowa Arayuwa Edukugho et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edukugho</LastName><ForeName>Aboyowa Arayuwa</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Federal Capital Territory (FCT), Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etapelong</LastName><ForeName>Sume Gerald</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>World Health Organization, Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gidado</LastName><ForeName>Saheed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Federal Capital Territory (FCT), Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbott</LastName><ForeName>Samuel Luka</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Federal Capital Territory (FCT), Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamisu</LastName><ForeName>Abdullahi Walla</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>World Health Organization, Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Isiaka Ayodeji</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>World Health Organization, Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mawashi</LastName><ForeName>Kabir Yusuf</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>National Primary Healthcare Development Authority, Federal Capital Territory (FCT), Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erbeto</LastName><ForeName>Tesfaye Bedada</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>World Health Organization, Country Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waziri</LastName><ForeName>Ndadilnasiya Endie</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Federal Capital Territory (FCT), Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguku</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Federal Capital Territory (FCT), Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omotayo</LastName><ForeName>Bolu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, Georgia, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamu</LastName><ForeName>Usman Said</ForeName><Initials>US</Initials><AffiliationInfo><Affiliation>National Primary Healthcare Development Authority, Federal Capital Territory (FCT), Abuja, Nigeria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Uganda</Country><MedlineTA>Pan Afr Med J</MedlineTA><NlmUniqueID>101517926</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009549" MajorTopicYN="N" Type="Geographic">Nigeria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010243" MajorTopicYN="N">Paralysis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute Flaccid Paralysis surveillance</Keyword><Keyword MajorTopicYN="N">COVID-19 pandemic</Keyword><Keyword MajorTopicYN="N">innovative</Keyword><Keyword MajorTopicYN="N">polio eradication</Keyword><Keyword MajorTopicYN="N">strategies</Keyword><Keyword MajorTopicYN="N">surveillance officers</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>20</Day><Hour>11</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>4</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38370097</ArticleId><ArticleId IdType="pmc">PMC10874093</ArticleId><ArticleId IdType="doi">10.11604/pamj.supp.2023.45.2.38261</ArticleId><ArticleId IdType="pii">PAMJ-45-10</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization Poliomyelitis (polio) Accessed September 7 2023.</Citation></Reference><Reference><Citation>Hussain SF, Boyle P, Patel P, Sullivan R. Eradicating polio in Pakistan: an analysis of the challenges and solutions to this security and health issue. Glob Health. 2016;12(1):63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5059991</ArticleId><ArticleId IdType="pubmed">27729081</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO EMRO Strategy | Polio eradication initiative. Accessed December 4 2020.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention Polio (Poliomyelitis) Accessed September 7 2023.</Citation></Reference><Reference><Citation>Nimpa MM, Razafiarivao NR, Robinson A, Fidiniaina MR, Razafindratsimandresy R, Masembe YV, et al. Efforts Towards Polio Eradication in Madagascar: 1997 to 2017. J Immunol Sci. 2021 Apr 13;(Spec Issue(2)):1102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610765</ArticleId><ArticleId IdType="pubmed">33997860</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO | Regional Office for Africa . Polio Eradication: Africa Regional Certification Commission begins verification visit to Nigeria. Accessed October 23 2021.</Citation></Reference><Reference><Citation>WHO | Regional Office for Africa Polio. Accessed October 23 2021.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative Global Polio Surveillance Action Plan 2018-2020. Accessed October 23, 2021.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative GPEI-Surveillance Indicators. Accessed December 4 2020.</Citation></Reference><Reference><Citation>Tuma JN, Wilkinson AL, Diop OM, Jorba J, Gardner T, Snider CJ, et al. Surveillance to Track Progress Toward Polio Eradication-Worldwide, 2019-2020. MMWR Morb Mortal Wkly Rep. 2021 May 7;70(18):667–673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9368747</ArticleId><ArticleId IdType="pubmed">33956779</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamisu AW, Johnson TM, Craig K, Fiona B, Richard B, Tegegne SG, et al. Sensitivity of Acute Flaccid Paralysis Surveillance in Nigeria (2006-2015) J Infect Dis Treat. 2016;2(2):13.</Citation></Reference><Reference><Citation>Leke RGF, King A, Pallansch MA, Tangermann RH, Mkanda P, Chunsuttiwat S, et al. Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world. Lancet Glob Health. 2020 Oct;8(10):e1345–e1351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7525084</ArticleId><ArticleId IdType="pubmed">32916086</ArticleId></ArticleIdList></Reference><Reference><Citation>Healio pediatrics . "A momentous milestone": Africa declared free of wild poliovirus. Accessed October 23 2021.</Citation></Reference><Reference><Citation>The Guardian Nigeria News WHO finally declares Nigeria. African Region free of wild polio virus. Accessed October 23, 2021.</Citation></Reference><Reference><Citation>World Health Organization . Archived: WHO Timeline - COVID-19. Accessed December 1 2020.</Citation></Reference><Reference><Citation>World Health Organization WHO Director-General´s opening remarks at the media briefing on COVID-19 - March 11 2020. Accessed November 30 2020.</Citation></Reference><Reference><Citation>Jee Y. WHO International Health Regulations Emergency Committee for the COVID-19 outbreak. Epidemiol Health. 2020;42:e2020013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7285442</ArticleId><ArticleId IdType="pubmed">32192278</ArticleId></ArticleIdList></Reference><Reference><Citation>Elimian KO, Ochu CL, Ilori E, Oladejo J, Igumbor E, Steinhardt L, et al. Descriptive epidemiology of coronavirus disease 2019 in Nigeria 27 February-6 June 2020. Epidemiol Infect. 2020 Sep 11;148:e208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7506173</ArticleId><ArticleId IdType="pubmed">32912370</ArticleId></ArticleIdList></Reference><Reference><Citation>Nigeria Centre for Disease Control and Prevention COVID-19. Accessed September 7 2023.</Citation></Reference><Reference><Citation>Ibrahim RL, Ajide KBello, Olatunde Julius O. Easing of lockdown measures in Nigeria: Implications for the healthcare system. Health Policy Technol. 2020;9(4):399–404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7490626</ArticleId><ArticleId IdType="pubmed">32959012</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative . Interim guide: May 2020 update v2.0. Polio eradication programme continuity: implementation in the context of the COVID-19 pandemic. Accessed September 7, 2023.</Citation></Reference><Reference><Citation>Nigeria: The African giant Round Table. 1959;50(197):55–63.</Citation></Reference><Reference><Citation>WHO | Regional Office for Africa Nigeria´s Polio laboratories pass another round of accreditation exercise. Accessed August 1 2021.</Citation></Reference><Reference><Citation>Nigeria Centre for Disease Control and Prevention Federal Ministry of Health. Coronavirus Disease (COVID-19) Prevention. Accessed September 7 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>